Fig. 6From: First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysisAdverse events (The risk of adverse events was comparable between the two groups (Fig. 6 a and b)Back to article page